CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased ...

CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, ...

When the coronavirus pandemic first took hold, trying to get a COVID test was like trying to get Glastonbury tickets. Hard to come by is an understatement. But now, well over a year on, a key part of ...

Only a few years ago the benefits of lateral flow diagnostic tests weren’t widely understood outside of scientific circles. The reason most people came into contact with the technology was through the ...